Neihumicin, with the CAS number 111451-12-8, is a naturally occurring antibiotic that belongs to the class of compounds known as aminoglycosides. It is produced by certain strains of the bacterium Micromonospora. Neihumicin exhibits antibacterial properties, particularly against a range of Gram-positive and some Gram-negative bacteria, making it of interest in the field of medicinal chemistry and antibiotic development. The compound functions by inhibiting bacterial protein synthesis, which is crucial for bacterial growth and replication. Its structure features multiple amino sugar moieties, contributing to its solubility and interaction with bacterial ribosomes. Neihumicin has been studied for its potential therapeutic applications, particularly in treating infections caused by resistant bacterial strains. However, like many antibiotics, its use may be limited by issues of resistance and toxicity, necessitating careful consideration in clinical applications. Further research is ongoing to explore its full potential and optimize its use in antibiotic therapy.

Neihumicin is  a new cytotoxic antibiotic from Micromonospora neihuensis.

Neihumicin

111451-12-8: Neihumicin, with the CAS number 111451-12-8, is a naturally occurring antibiotic that belongs to the class of compounds known as aminoglycosides. It is produced by certain strains of the bacterium Micromonospora. Neihumicin exhibits antibacterial properties, particularly against a range of Gram-positive and some Gram-negative bacteria, making it of interest in the field of medicinal chemistry and antibiotic development. The compound functions by inhibiting bacterial protein synthesis, which is crucial for bacterial growth and replication. Its structure features multiple amino sugar moieties, contributing to its solubility and interaction with bacterial ribosomes. Neihumicin has been studied for its potential therapeutic applications, particularly in treating infections caused by resistant bacterial strains. However, like many antibiotics, its use may be limited by issues of resistance and toxicity, necessitating careful consideration in clinical applications. Further research is ongoing to explore its full potential and optimize its use in antibiotic therapy.

<p>Neihumicin exhibits resistance against the yeast Saccharomyces cerevisiae (ATCC 9763) and the mold Penicillium italicum (Wehmer), but it does not show resistance to bacteria.</p>

CAS 111451-12-8

Neihumicin

Neihumicin

Ref: TM-TN10550